Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Estrogen alpha receptor antagonists for the treatment of breast cancer: a review.

Sharma D, Kumar S, Narasimhan B.

Chem Cent J. 2018 Oct 25;12(1):107. doi: 10.1186/s13065-018-0472-8. Review.

2.
3.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
4.

Mouse models of estrogen receptor-positive breast cancer.

Mohibi S, Mirza S, Band H, Band V.

J Carcinog. 2011;10:35. doi: 10.4103/1477-3163.91116. Epub 2011 Dec 22.

5.

Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.

May FE.

Cancer Manag Res. 2014 May 23;6:225-52. doi: 10.2147/CMAR.S35024. eCollection 2014. Review.

6.

Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents.

Dube PN, Sakle NS, Dhawale SA, More SA, Mokale SN.

Anticancer Agents Med Chem. 2019;19(9):1150-1160. doi: 10.2174/1871520619666190307121145.

PMID:
30848213
7.

William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer.

Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM.

Breast Cancer Res Treat. 1997 May;44(1):23-38. Review.

PMID:
9164675
9.

Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.

Saha P, Fortin S, Leblanc V, Parent S, Asselin É, Bérubé G.

Steroids. 2012 Sep;77(11):1113-22. doi: 10.1016/j.steroids.2012.06.004. Epub 2012 Jul 16.

PMID:
22801351
10.

Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

Patel HK, Bihani T.

Pharmacol Ther. 2018 Jun;186:1-24. doi: 10.1016/j.pharmthera.2017.12.012. Epub 2017 Dec 28. Review.

11.

MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.

Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, Maggiolini M.

Breast Cancer Res. 2012 Jan 17;14(1):R12.

12.

Hormone binding and transcription activation by estrogen receptors: analyses using mammalian and yeast systems.

Katzenellenbogen BS, Bhardwaj B, Fang H, Ince BA, Pakdel F, Reese JC, Schodin D, Wrenn CK.

J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):39-48. Review.

PMID:
8274440
14.

Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.

Ma Y, Tomita Y, Preet A, Clarke R, Englund E, Grindrod S, Nathan S, De Oliveira E, Brown ML, Rosen EM.

Mol Endocrinol. 2014 Dec;28(12):1971-86. doi: 10.1210/me.2014-1146.

15.

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.

Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ.

Breast Cancer Res. 2010;12(3):R32. doi: 10.1186/bcr2586. Epub 2010 Jun 4.

16.
17.

Estrogen signaling: An emanating therapeutic target for breast cancer treatment.

Saha T, Makar S, Swetha R, Gutti G, Singh SK.

Eur J Med Chem. 2019 Sep 1;177:116-143. doi: 10.1016/j.ejmech.2019.05.023. Epub 2019 May 11. Review.

PMID:
31129450
18.
19.
20.

Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.

Suba Z.

Recent Pat Anticancer Drug Discov. 2017;12(2):136-147. doi: 10.2174/1574892812666170227110842. Review.

PMID:
28245776

Supplemental Content

Support Center